doi: 10.3892/IJMM.2025.5515 Summary Keywords glucagon-like peptide-1, type 2 diabetes, endothelial function, obesity, metabolic syndrome Citation Hammad BF, Zafar N, Ullah M, Faisal SJ, Iftikhar F, Waheed H, Muzaffar MW, Ahmed K, Ashraf F, Zahid K, Akhtar M and Mahmmoud Fadelallah Eljack M (2025) Exploring the multifaceted roles of GLP-1 receptor agonists
Each Capsule Provides
ADA 2025 Guideline Alignment: Cardiometabolic Prioritization The ADA 2025 framework reflects CVOT insights: Prioritize GLP-1 RAs with proven CV benefit and SGLT2 inhibitors for high-risk ASCVD , heart failure, and CKD For CKD , SGLT2 inhibitors remain first-line
Khodabakhshi, A
Lipsyc-Sharf, M
OZEMPIC must be kept in the original carton until time of administration